Fujirebio Diagnostics, Inc.
July 24, 2025 |
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools.
Fujirebioās tests for detecting amyloid pathology associated with Alzheimerās disease, the LumipulseĀ® G Ī²-Amyloid Ratio (1-42/1-40) test for CSF, and the LumipulseĀ® G pTau 217/Ī²-Amyloid 1-42 Plasma Ratio test, were the first FDA-cleared in vitro diagnostic tests for CSF and plasma, respectively.
More information can be found at www.fujirebio.com.